Compounds and methods for treatment of primary biliary cholangitis
US11534424B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 16, 2018 |
| Grant date | Dec 27, 2022 |
| Priority date | — |
| Expiry date | Feb 16, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/575
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to, inter alia, methods of treatment and combinations of (R)-2-(7-(4-cyclopentyl-3-(tri-fluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) useful for the treatment of primary biliary cholangitis (PBC). In some embodiments, the methods further comprise administering Compound 1, or a pharmaceutically salt, solvate, or hydrate thereof, in combination with a compound selected from the group consisting of: an antihistamine (diphenhydramine), cholestyramine (questran, prevalite), rifampin, an opioid antagonist (naloxone), pilocarpine (isopto carpine, salagen), cevimeline (evoxac), calcium and/or vitamin D supplement, and vitamin A, D, E and/or K supplement. Other embodiments, relate to titration packages for enabling compliance with a regimen of changing dosage of a medication over a period of time for the treatment of primary biliary cholangitis (PBC).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.